menu
    • menu
    [{"orgOrder":0,"company":"Gadeta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Gamma delta T-cell receptor based immunotherapies","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gadeta \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ Not Applicable"},{"orgOrder":0,"company":"Gadeta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"GDT002","moa":"Gamma Delta T cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Gadeta \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Gadeta \/ Not Applicable"},{"orgOrder":0,"company":"Gadeta","sponsor":"Immunocore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"GDT201","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Gadeta \/ Gadeta","highestDevelopmentStatusID":"4","companyTruncated":"Gadeta \/ Gadeta"},{"orgOrder":0,"company":"Gadeta","sponsor":"Clade Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"TEG002","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gadeta \/ Clade Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ Clade Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Gadeta

    Menu

    Gadeta

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gadeta

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Gadeta

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TEG002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Clade Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Clade Therapeutics Announces the Acquisition of Gadeta B.V.

                            Details : The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies.

                            Brand Name : GDT002

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 02, 2023

                            Lead Product(s) : TEG002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Clade Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gadeta

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Gadeta

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GDT201,Tebentafusp-tebn

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Immunocore

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors

                            Details : Gadeta is developing ‘201 TCR in its proprietary TEG (T Cells Engineered to Express a Defined Gamma Delta TCR) cell therapy platform as GDT201. Pre-clinical data for GDT201 show promising results across a wide range of colorectal cancer cell lines.

                            Brand Name : GDT201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 02, 2022

                            Lead Product(s) : GDT201,Tebentafusp-tebn

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Immunocore

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gadeta

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Gadeta

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GDT002

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences

                            Details : GDT002 has a potent anti-tumor activity across a broad spectrum of solid and liquid tumor types as well as to discuss the data behind our decision to select ovarian cancer as an indication to explore the clinical effect of GDT002 against solid tumors.

                            Brand Name : GDT002

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 28, 2022

                            Lead Product(s) : GDT002

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gadeta

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Gadeta

                            Netherlands arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma delta T-cell receptor based immunotherapies

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Dosed with Gadeta's Gamma Delta TCR Cell Therapy

                            Details : The multicenter phase 1/2 study in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care and Beth Israel Deaconess Medical Center, is evaluating safety, tolerability and preliminary efficacy of GDT-002 for the treatment of...

                            Brand Name : GDT-002

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 06, 2021

                            Lead Product(s) : Gamma delta T-cell receptor based immunotherapies

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth